Predicting neurocognitive function in pediatric brain tumor early survivorship: The neurological predictor scale and the incremental validity of tumor size.
Predicting neurocognitive function in pediatric brain tumor early survivorship: The neurological predictor scale and the incremental validity of tumor size.
复制标题
DOI：
10.1002/pbc.29803
复制
发表时间：
2022-09
影响因子：
3.2
通讯作者：
中科院分区：
文献类型：
--
作者：
神经预测量表（NPS）量化了传统治疗相关神经风险的累积暴露，但没有捕捉肿瘤本身带来的潜在风险。这项研究评估了 NPS 的预测有效性，以及肿瘤位置和大小的增量值，对儿童脑肿瘤当代治疗后早期生存的神经认知结果。 2010 年至 2016 年诊断出的幸存者 (N=69) 接受了适合年龄版本的韦克斯勒智力量表。分层多元回归检验了 NPS 评分、肿瘤位置和肿瘤大小的预测和增量有效性。年龄 6-20 岁的参与者（51% 女性）（M=13.22，SD=4.09）在诊断后 5.16 年（SD=1.29）完成神经认知评估。在控制性别、诊断年龄和母亲受教育程度后，NPS 显着预测了全面智商 (FSIQ; )、言语理解指数 (VCI; )、知觉推理指数 (PRI; ) 和处理速度指数 (PSI; ) 表现。除了 NPS 和相关协变量捕获的差异之外，仅肿瘤大小就导致了 FSIQ 和 PSI 的大量独特方差。在完整模型中，NPS 仍然是 FSIQ (β=−.249，p=.016)、VCI (β=−.223，p =.048) 的显着独立预测因子。和 PRI（β=−.229，p=.037）。肿瘤大小成为神经认知功能的独立预测因子，并逐渐增强了 NPS 的预测效用。治疗前的疾病负担可能是当代治疗后神经认知风险的最早标志之一。随着治疗的不断进步，量化治疗相关风险的措施可能需要更新和重新验证，以维持其临床效用。
The Neurological Predictor Scale (NPS) quantifies cumulative exposure to conventional treatment-related neurological risks but does not capture potential risks posed by tumors themselves. This study evaluated the predictive validity of the NPS, and the incremental value of tumor location and size, for neurocognitive outcomes in early survivorship following contemporary therapies for pediatric brain tumors. Survivors (N=69) diagnosed from 2010–2016 were administered age-appropriate versions of the Wechsler Intelligence Scales. Hierarchical multiple regressions examined the predictive and incremental validity of NPS score, tumor location, and tumor size. Participants (51% female) aged 6–20 years (M=13.22, SD=4.09) completed neurocognitive evaluations 5.16 years (SD=1.29) post-diagnosis. The NPS significantly predicted Full Scale Intelligence Quotient (FSIQ; ), Verbal Comprehension Index (VCI; ), Perceptual Reasoning Index (PRI; ), and Processing Speed Index (PSI; ) performance after controlling for sex, age at diagnosis, and maternal education. Tumor size alone accounted for a significant amount of unique variance in FSIQ , and PSI , beyond that captured by the NPS and relevant covariates. Within the full model, the NPS remained a significant independent predictor of FSIQ (β=−.249, p=.016), VCI (β=−.223, p =.048). and PRI (β=−.229, p=.037). Tumor size emerged as an independent predictor of neurocognitive functioning and added incrementally to the predictive utility of the NPS. Pre-treatment disease burden may provide one of the earliest markers of neurocognitive risk following contemporary treatments. With perpetual treatment advances, measures quantifying treatment-related risk may need to be updated and re-validated to maintain their clinical utility.
登录
查看更多内容
影响因子：
15.9
作者：
Dolecek, Therese A.;Propp, Jennifer M.;Kruchko, Carol
通讯作者：
Kruchko, Carol
DOI：
10.1017/s1355617716000138
发表时间：
2016-05-01
影响因子：
2.6
作者：
Ailion, Alyssa S.;King, Tricia Z.;Crosson, Bruce
通讯作者：
Crosson, Bruce
影响因子：
1.9
作者：
Micklewright, Jackie L.;King, Tricia Z.;Krawiecki, Nicolas
通讯作者：
Krawiecki, Nicolas
影响因子：
3.8
作者：
Olsson, Ingrid Tonning;Perrin, Sean;Johanson, Aid
通讯作者：
Johanson, Aid
影响因子：
15.9
作者：
Palmer, Shawna L.;Hassall, Tim;Gajjar, Amar
通讯作者：
Gajjar, Amar